Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

At Novartis, CEO Vas Narasimhan’s overall 2024 pay increased by 6.9% at grant value, reaching 14.2 million Swiss francs ($15.7 million), according to the company’s annual report (PDF).

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

The comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last year, and he wants to keep up that momentum. Speaking on Novartis ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...

In 2024, Bayer chief Bill Anderson’s total compensation fell about 21% to 8.84 million euros ($9.6 million). The decline ...

Novartis chief executive Vas Narasimhan, already eyeing a possible divestment of generics business Sandoz, has now turned his attention to the rest of the company. The Swiss group will see major ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, ...

In response, Novartis CEO Vas Narasimhan, M.D., said, “We’ve had to give the appropriate level of adjustments on our rebates, but we've maintained [a] very good formulary position,” adding ...

In this article, we will look at the 11 Best Undervalued Stocks to Invest in Now.

Novartis CEO Vas Narasimhan received a total of 19.1 million Swiss Francs — or $21.4 million — in total compensation in 2024. This marked a 40% increase from his $15.3 million total compensation in ...